MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Relay Therapeutics Inc

Затворен

СекторЗдравеопазване

3.52 0.57

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.31

Максимум

3.59

Ключови измерители

By Trading Economics

Приходи

-1.1M

-77M

Продажби

7.7M

7.7M

EPS

-0.455

Марж на печалбата

-1,003.581

Служители

259

EBITDA

-1.2M

-85M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+275.15% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-7.2M

547M

Предишно отваряне

2.95

Предишно затваряне

3.52

Настроения в новините

By Acuity

50%

50%

164 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Relay Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.06.2025 г., 21:26 ч. UTC

Значими двигатели на пазара

AeroVironment Shares Slide on Stock, Notes Offerings

30.06.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

BBVA Won't Withdraw Sabadell Offer

30.06.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30.06.2025 г., 23:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

30.06.2025 г., 23:03 ч. UTC

Печалби

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30.06.2025 г., 22:50 ч. UTC

Придобивния, сливания и поглъщания

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30.06.2025 г., 22:50 ч. UTC

Печалби

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30.06.2025 г., 21:26 ч. UTC

Печалби

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.06.2025 г., 19:46 ч. UTC

Пазарно говорене

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30.06.2025 г., 19:16 ч. UTC

Пазарно говорене

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30.06.2025 г., 19:10 ч. UTC

Пазарно говорене

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30.06.2025 г., 19:07 ч. UTC

Пазарно говорене

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30.06.2025 г., 18:27 ч. UTC

Пазарно говорене

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30.06.2025 г., 17:08 ч. UTC

Придобивния, сливания и поглъщания

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30.06.2025 г., 17:00 ч. UTC

Придобивния, сливания и поглъщания

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30.06.2025 г., 16:41 ч. UTC

Пазарно говорене

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30.06.2025 г., 16:32 ч. UTC

Пазарно говорене

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30.06.2025 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30.06.2025 г., 16:22 ч. UTC

Придобивния, сливания и поглъщания

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.06.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

30.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

30.06.2025 г., 16:07 ч. UTC

Печалби

Umicore to Post 1H Results on Aug 1

30.06.2025 г., 15:59 ч. UTC

Пазарно говорене

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30.06.2025 г., 15:55 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30.06.2025 г., 15:54 ч. UTC

Пазарно говорене

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30.06.2025 г., 15:41 ч. UTC

Придобивния, сливания и поглъщания

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Relay Therapeutics Inc Прогноза

Ценова цел

By TipRanks

275.15% нагоре

12-месечна прогноза

Среден 12.38 USD  275.15%

Висок 17 USD

Нисък 4 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Relay Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

8

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

2.88 / 3.285Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

164 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.